Nagoba Basavraj S, Rayate Abhijit S
Department of Microbiology, Maharashtra Institute of Medical Sciences & Research (Medical College), Latur 413531, India.
Department of Surgery, Maharashtra Institute of Medical Sciences & Research (Medical College), Latur 413531, India.
World J Virol. 2024 Jun 25;13(2):90951. doi: 10.5501/wjv.v13.i2.90951.
Hepatitis E virus (HEV) infection is now endemic worldwide. Most patients with acute infection recover uneventfully. Outbreaks and sporadic cases, particularly in high-risk individuals are emerging increasingly. The patients with risk factors like pregnancy and pre-existing chronic liver disease, present with or progress rapidly to severe disease. Immuno-suppression in post-transplant patients is an additional risk factor. Standardized FDA-approved diagnostic tests are the need of the hour. Further studies are needed to establish guideline-based treatment regimen and outbreak preparedness for HEV to decrease global morbidity, mortality, and healthcare burden. Policies for screening donors and transplant cases are required.
戊型肝炎病毒（HEV）感染目前在全球呈地方性流行。大多数急性感染患者可顺利康复。疫情暴发和散发病例日益增多，尤其是在高危个体中。有妊娠和既往慢性肝病等危险因素的患者，会出现严重疾病或病情迅速进展。移植后患者的免疫抑制是另一个危险因素。目前急需经美国食品药品监督管理局（FDA）批准的标准化诊断检测方法。需要进一步开展研究，以建立基于指南的戊型肝炎治疗方案和疫情防范措施，从而降低全球发病率、死亡率和医疗负担。需要制定筛查供体和移植病例的政策。
